ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

FAB Fusion Antibodies Plc

3.275
0.00 (0.00%)
Last Updated: 08:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Fusion Antibodies Plc LSE:FAB London Ordinary Share GB00BDQZGK16 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.275 3.25 3.30 3.275 3.275 3.28 11,234 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 2.9M -2.6M -0.0437 -0.75 1.94M
Fusion Antibodies Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FAB. The last closing price for Fusion Antibodies was 3.28p. Over the last year, Fusion Antibodies shares have traded in a share price range of 3.10p to 50.00p.

Fusion Antibodies currently has 59,453,714 shares in issue. The market capitalisation of Fusion Antibodies is £1.94 million. Fusion Antibodies has a price to earnings ratio (PE ratio) of -0.75.

Fusion Antibodies Share Discussion Threads

Showing 4051 to 4074 of 4075 messages
Chat Pages: 163  162  161  160  159  158  157  156  155  154  153  152  Older
DateSubjectAuthorDiscuss
01/5/2024
13:55
Great price down here
bobaxe1
30/4/2024
16:35
bobaxe1,

"On the contrary that was a strong update."

Is that why the share price crashed 10% on the day? Because it was a "strong update"?

What in particular did you think was "strong"? Was it the revenue news?

"Unaudited revenues for FY2024 of £1.14m (FY2023: £2.90m)"

^^ Down over 60%!

"Significant increase in sales pipeline opportunities during H2 FY2024, with an orderbook at 31 March 2024 of £0.75m, representing 65 per cent. of total FY2024 unaudited revenues"

^^ A trivial sales pipeline that's less than my local sandwich shop!

"Cash position as at 31 March 2024 of £1.2m (31 March 2023: £0.2m)"

^^ They've already started to burn through the £1.37m of funds that were raised in Feb!

At best we're twelves months away from the next fund raise. At worst your fellow shareholders will finally cotton on that this is a total basket case that's not worth supporting.

JakNife

jaknife
30/4/2024
13:47
On the contrary that was a strong update. The company has raised well above the current share price at 5.66 . Cash is great going forward had our best month earnings in years delayed earnings will arrive. So just sitting oversold with the usual trolls giving their pennies worth
bobaxe1
30/4/2024
12:59
Yet another poor trading update for this POS company:



It's not true what the adverts say that "past performance is not a guide to future performance", it is 100% the case that "once a dog, always a dog"!

JakNife

jaknife
15/4/2024
15:04
Royalties have the potential to bring in much higher revenues, good choice by the company, I expect many more contracts to start feeding through.
deltalo
15/4/2024
11:36
What is the upfront value???
inaminute
15/4/2024
10:56
Great news this morning I have had another top up more to follow
bobaxe1
15/4/2024
07:29
It’s a new technology and second strand of their Optimal programme alongside the AI

OptiPhageTM, a phage display based version of the same DNA library. OptiPhageTM uses the same DNA sequences as OptiMAL® but packages them into a more commonly used Phage display format. Only smaller antibody fragments can be screened in this way, compared to whole antibodies via OptiMAL®, but it can be run at a lower price point for the customer. The Directors believe that the provision of OptiPhageTM provides the Company with an ability to protect the premium pricing of the OptiMAL® programme whilst meeting budgetary constraints of its customers. It may also be the platform of choice for those wanting antibody fragments as their end product;

gtc1508
15/4/2024
07:23
Nice contract - not much upfront in terms of value, but royalties seems a good model
paulisi
15/4/2024
07:20
Excellent news this is the start of the recovery
bigjock36
10/4/2024
11:04
Interesting pickup today
ksddw2
04/4/2024
21:30
Good chart here !//https://x.com/darrenukdaytra1/status/1775849435609677990?s=46&t=KHNNXk1Nw1j5lyzHBSnKag
bobaxe1
02/4/2024
15:00
Just read your last 10 posts, another bot for the filter bin...
troutisout
02/4/2024
14:56
Yep fab considering delisting needs shareholder vote to agree
beatme1
02/4/2024
10:31
They do not have billions of shares
bobaxe1
02/4/2024
09:51
Bought APH , Alliance Pharma plc , growing profitable health care company
blackhorse23
02/4/2024
08:38
Hearing fab want to delist following other pharma stocks
beatme1
22/3/2024
18:56
I agree I bought at 3.73Fully funded and ready for a re-rate
bigjock36
22/3/2024
14:48
No brainier down here
bobaxe1
21/3/2024
13:36
According to the financials we have 10x cash to Mcap surly that is not so ?
bobaxe1
15/3/2024
16:03
Just topped up shows red good price not complaining
bobaxe1
14/3/2024
13:22
https://x.com/fsnantibodies/status/1768264192648171934?s=46&t=KHNNXk1Nw1j5lyzHBSnKag
bobaxe1
07/3/2024
12:19
Looking good, I think they want to take it higher
soultrading
07/3/2024
08:37
Picking up here
bobaxe1
Chat Pages: 163  162  161  160  159  158  157  156  155  154  153  152  Older

Your Recent History

Delayed Upgrade Clock